Here is the latest news about the Montreal Heart Institute.

Subscribe to news feed
  • New Clinical Trial on Hesperidin

    February 16, 2021

    A natural product to fight symptoms related to COVID-19

    The Montreal Heart Institute (MHI) is launching a new clinical trial to evaluate the effect of hesperidin on symptoms related to COVID-19. This flavonoid naturally found in citrus fruits has distinct properties that may reduce the entry and replication of the SARS-CoV2 virus in the body along with the modulation of inflammatory mediators, thus potentially reducing symptoms and prevent complications from the disease.

    Read more

  • Caregiver visits suspended at 3rd East and 3rd Center

    January 29, 2021

    Due to an outbreak in the surgical continuum, caregiver visits are suspended indefinitely.

    Caregivers will not be able to come to the surgical intensive care unit (3rd east) and the surgical unit (3rd center) until further notice.

    In exceptional situations or for humanitarian reasons (eg: end of life), a caregiver may be authorized, with the agreement of the care unit.

    Read more

  • Major scientific breakthrough to treat COVID-19

    January 27, 2021

    UPDATE: COLCORONA study manuscript is now available in the public domain.


    On January 22, 2021, the Montreal Heart Institute announced positive results from COLCORONA trial. These results showed that colchicine is the only effective oral medication for treating non-hospitalized patients.

    Read more

  • A new discovery in heart muscle disease

    January 26, 2021

    This medical breakthrough could help prevent the leading cause of sudden death in young people.

    An international team of researchers co-led by Dr. Rafik Tadros, Cardiologist at the Montreal Heart Institute and Assistant Professor at the Université de Montréal, has identified new genetic traits associated with heart muscle disease (cardiomyopathy). This breakthrough, published today in the prestigious scientific journal Nature Genetics, could have a significant impact in the development of drugs against this disease whose mechanisms are still little known.

    Read more

  • Colchicine reduces the risk of COVID-19-related complications

    January 23, 2021

    Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

    Read more

  • Second year of the Montreal Heart Institute’s Diabetes Prevention Clinic sponsored by Sun Life

    January 15, 2021

    Supporting people with type 2 diabetes throughout the pandemic

    Read more

  • New data supports development of colchicine for the prevention of acute respiratory distress syndrome

    December 7, 2020

    This syndrome can develop in patients with COVID-19 if the virus enters the respiratory tract and damages the lungs

    The Montreal Heart Institute (MHI) has announced that colchicine, a widely available low-cost drug, reduces acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and respiratory failure in pre-clinical models1. The article reporting these results was published yesterday by the Public Library of Science ONE (PLOS ONE) 1.

    Read more

  • Colchicine shows promise as a treatment for at-home COVID-19 patients

    November 29, 2020

    Recruitment of participants in the COLCORONA phase 3 study likely to end in 2020

    The Montreal Heart Institute (MHI) today announced that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the independent data monitoring committee (DMC), following a second interim analysis.

    Read more

  • Early Invasive Intervention for Atrial Fibrillation may Improve Patient Outcomes and Provide a Better Quality of Life

    November 16, 2020

    Doctors from the Montreal Heart Institute (MHI) presented new data today at the American Heart Association Late-Breaking Scientific Sessions. Simultaneously published in the New England Journal of Medicine, the data shows that catheter ablation as first-line treatment may be better than antiarrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.

    Read more

  • CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials

    November 5, 2020

    A collaboration between Perceiv AI, DalCor Pharmaceuticals and the Montreal Heart Institute

    The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool.

    Read more